[ET Net News Agency, 18 May 2026] Citi lowered the target price for Ali Health (00241) to HKD8 from HKD9 and maintained the "buy/high risk" rating.
The research house said it fine-tunes revenue estimates and cuts EPS by 8%/11% in FY27/28 to reflect higher selling and R&D costs for innovative drug and medical AI. (rc)
The research house said it fine-tunes revenue estimates and cuts EPS by 8%/11% in FY27/28 to reflect higher selling and R&D costs for innovative drug and medical AI. (rc)